Navigation Links
Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
Date:11/14/2011

a strongly support further development of Virobay's spectrum-selective cathepsin inhibitors in metastatic and primary bone cancer, and that this novel therapeutic approach may be especially valuable in combination with existing anticancer approaches."

VBY-825 is a member of a series of highly potent, spectrum-selective cathepsin inhibitors with structural diversity, which is being developed by Virobay.  Increased cathepsin levels and activity have been shown to play a role in a variety of tumors, including lung and breast, and are correlated to poor patient prognosis.  The proteolytic activity of multiple cathepsins may play a role in degradation of the basement membrane and extracellular matrix allowing a loss of cell adhesion and facilitating tumor metastasis.  Cathepsin K inhibition has been shown to suppress bone resorption in women with post-menopausal osteoporosis as well as women with breast cancer by inhibiting osteoclast function.  Studies with cathepsin S inhibitors have demonstrated a reduction in the perception of pain (nociception) in animals, with no sedating effects, suggesting a role for cathepsin S in neuropathic and inflammatory pain.

About Virobay

Virobay is a leader in the design, synthesis and development of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases that are key mediators in a variety of diseases, including autoimmunity, neuropathic pain, liver disease, cancer, and cardiovascular disorders.  Virobay was founded upon a rich industry legacy of intensive research and development focused on the cathepsin family of cysteine proteases.  Today, Virobay possesses a trove of maturing assets, including an advancing clinical pipeline and well-characterized libraries of highly potent and selective inhibitors with drug-like pharmacokinetics consistent with the potential for oral once-daily dosing in humans.

Virobay's unique expertise in the structure
'/>"/>

SOURCE Virobay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Study Shows C1-Esterase Inhibitor Concentrate is Safe and Consistently Effective for Long-Term Treatment of Hereditary Angioedema Attacks at Any Body Location
3. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
4. ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV
5. Enantas Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhovers Top 10 Infectious Disease Projects to Watch
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. Modulation of inhibitory output is key function of antiobesity hormone
8. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
9. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
10. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
11. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global Human Albumin Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth study ... industry. The report provides a basic overview ... chain structure. The human albumin market analysis is provided ...
(Date:9/18/2014)... 2014  U.S. biotech company Kultevat has ... for technology developed by the Donald Danforth Plant ... including for applications in production of natural rubber in ... was developed under the direction of Roger Beachy ... president of the Danforth Plant Science Center, and is ...
(Date:9/18/2014)... - Oncothyreon Inc. (NASDAQ: ONTY ) today ... underwritten offerings of 10,000,000 shares of its Common Stock ... share, for expected gross proceeds of $20 million and ... at a price to the public of $2,000.00 per ... share of Series A Convertible Preferred Stock is non-voting ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
... - Only Nasal Powder Bird Flu Vaccine Under Development ... No Preservatives - Stable at Room Temperature For 3 Years; No Cold Chain ... ... Bulletin Board: CARN) today announced that its,wholly-owned subsidiary DelSite Biotechnologies, Inc. received a shipment,of ...
... Visits Each Year, East Coast,s Largest Independent Clinical ... ... CEDAR KNOLLS, N.J., Feb. 14 MedeFile,International, Inc. ... medical records management solutions, today announced,that it has signed ...
... Shenzhen Beike,Biotechnology Co., Ltd. ( http://www.beikebiotech.com ... cord stem cells to successfully treat a variety ... Mayor of,Manchester, has returned today to the United ... life-threatening condition known as,cerebellar atrophy. As the latest ...
Cached Biology Technology:Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 2Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 3Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 4Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 2Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 3Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 4Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility 2Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility 3
(Date:9/17/2014)... health care to reproductive technologies, the justice and ... of people to identify key issues, articulate their ... find the most defensible ways forward. But what ... societal conversations?, The Hastings Center and the Presidential ... teamed up to publish a series of essays ...
(Date:9/17/2014)... Fauna Europaea started in 2000 as an EC-FP5 four-year ... years of steady progress and successful participations in several ... European Biodiversity Observation Network project (EU BON), to ... the contributors and to extend the general dissemination of ... Journal has applied its novel e-Publishing tools ...
(Date:9/17/2014)... research from the Copenhagen Centre for Social Evolution and ... theory that birth weight and -length can partially predict ... such as autism and schizophrenia later in life. The ... and subsequent hospital diagnoses for up to 30 years, ... The study is published today in the Proceedings ...
Breaking Biology News(10 mins):Why bioethics literacy matters 2Why bioethics literacy matters 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3
... a new synthetic metabolic pathway for breaking down glucose that ... of biofuels. The new pathway is intended ... series of chemical reactions that nearly all organisms use to ... converts four of the six carbon atoms found in glucose ...
... NASA,s Cassini spacecraft has detected propylene, a chemical used ... products, on Saturn,s moon Titan. This is the ... moon or planet, other than Earth. A small ... by Cassini,s Composite Infrared Spectrometer (CIRS). This instrument measures ...
... 30, 2013 UC Irvine scientists Aaron Esser-Kahn, Sunil ... the prestigious 2013 National Institutes of Health Director,s New ... projects by early-career researchers that show potential to transform ... new ways to improve human health. Esser-Kahn, Gandhi ...
Cached Biology News:UCLA engineers develop new metabolic pathway to more efficiently convert sugars into biofuels 2NASA's Cassini spacecraft finds ingredient of household plastic in space 2UCI achieves rare trifecta: 3 scientists receive New Innovator Awards 2
Request Info...
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
...
Biology Products: